Rising. AI Bio, a subsidiary, announced that it has signed an exclusive license agreement with South Korea's SML Biopharm to use the antibody gene sequence against severe fever with thrombocytopenia syndrome (SFTS) virus for therapeutic purposes. AI Bio has been seeking an early derivation for the development of therapeutic neutralizing antibodies against SFTS virus, a tick-borne infectious disease. The impact on the performance for the fiscal year ending March 2025 is slight because the contract includes a temporary fee reduction, but it is expected to contribute to the improvement of the company's long-term performance and enterprise value, which has attracted buying interest.
免疫生物研究所---続伸、子会社が韓国SML社とSFTSウイルス抗体遺伝子の独占的実施許諾契約締結
The Institute of Immunology has signed an exclusive licensing agreement with South Korean SML Company and SFTS virus antibody genes, with continued growth in its subsidiary.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.